Author(s): Lerman C, Wileyto EP, Patterson F, Rukstalis M, Audrain-McGovern J, et al.
To determine whether the functional mu-opioid receptor (OPRM1) Asn40Asp variant predicts the comparative efficacy of different forms of NRT, we conducted a clinical trial of transdermal nicotine (TN) vs nicotine nasal spray (NS) in 320 smokers of European ancestry. Smokers carrying the OPRM1 Asp40 variant (n=82) were significantly more likely than those homozygous for the Asn40 variant (n=238) to be abstinent at the end of treatment, and reported less mood disturbance and weight gain. The genotype effect on treatment outcome was most pronounced among smokers receiving TN, particularly during the 21 mg dose phase. Smokers who carry the OPRM1 Asp40 variant are likely to have a favorable response to TN and may benefit from extended therapy with the 21 mg dose.
Referred From: https://www.nature.com/articles/6500238
Author(s): Cloninger CR, Zohar AH
Author(s): Watson D, Clark LA, Tellegen A (1988a) Development and validation of brief measures of positive and negative affect: the PANAS scales
Author(s): Ranson MB, Nichols DS, Rouse SV, Harrington JL
Author(s): Scholtens S, Smidt N, Swertz MA, Bakker SJ, Dotinga A, et al.
Author(s): Berridge KC
Author(s): Trezza V, Baarendse PJJ, Vanderschuren LJMJ
Author(s): Nelson EE, Panksepp J
Author(s): Joëls M, Baram TZ
Author(s): Henry JD, von Hippel C, Terrett G, Mercuri K, McAlear K, et al.
Author(s): Henry MS, Bisht K, Vernoux N, Gendron L, Torres-Berrio A, et al.
Author(s): Mague SD, Blendy JA
Author(s): Eipper-Mains JE, Eipper BA, Mains RE
Author(s): Bühler M, Vollstädt-Klein S, Kobiella A, Budde H, Reed LJ, et al.
Author(s): Lutz PE, Kieffer BL
Author(s): Loseth GE, Ellingsen DM, Leknes S
Author(s): Peciña M, Love T, Stohler CS, Goldman D, Zubieta JK
Author(s): Stein C, Schafer M, Machelska H
Author(s): Nummenmaa L, Tuominen L
Author(s): Troisi A, Frazzetto G, Carola V, Di Lorenzo G, Coviello M, et al.
Author(s): Oertel BG, Kettner M, Scholich K, Renné C, Roskam B, et al.
Author(s): Tejeda HA, Wu J, Kornspun AR, Pignatelli M, Kashtelyan V, et al.
Author(s): Knoll AT, Carlezon Jr WA
Author(s): Hang Ai, Wang YJ, He L, Liu JG
Author(s): Vachon-Presseau E, Tétreault P, Petre B, Huang L, Berger SE, et al.
Author(s): Boomsma DI, Wijmenga C, Slagboom EP, Swertz MA, Karssen LC, et al.
Author(s): Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al.
Author(s): Albrechtsen A, Grarup N, Li Y, Sparsø T, Tian G, et al.
Author(s): Watson D, Clark LA, Carey G (1988b) Positive and negative affectivity and their relation to anxiety and depressive disorders
Author(s): Fitzcharles MA, Faregh N, Ste-Marie PA, Shir Y
Author(s): Bershad AK, Miller MA, Norman GJ, Wit HD
Author(s): Wen S1, Wang C, Berg A, Li Y, Chang MM, et al.
Author(s): Knoll AT, Meloni EG, Thomas JB, Carroll FI, Carlezon WA
Author(s): Mague SD, Pliakas AM, Todtenkopf MS, Tomasiewicz HC, Zhang Y, et al.
Author(s): Pfeiffer A, Brantl V, Herz A, Emrich HM
Author(s): Carr GV, Lucki I
Author(s): Jolly M, Verbeke W
Author(s): Deelen P, Menelaou A,Van Leeuwen EM, Kanterakis A, Van Dijk F, et al.
Author(s): Delaneau O, Zagury JF, Marchini J
Author(s): Del Boca C, Lutz PE, Le Merrer J, Koebel P, Kieffer BL
Author(s): Howie B, Fuchsberger C, Stephens M, Marchini J, Abecasis GR
Author(s): Schimmack U